Infeflox (Ceftriaxone)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to weakened cell walls, osmotic instability, and bacterial lysis. Its high affinity for multiple PBPs and resistance to many β‑lactamases give it activity against a wide range of Gram‑positive and Gram‑negative organisms.

The specific dose of Infeflox is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal and hepatic function, and local antimicrobial guidelines. Dosage may be administered once daily by intramuscular or intravenous injection, but exact regimens should follow the prescriber’s order.

Ceftriaxone is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It is generally considered safe when clearly needed, but the prescriber will weigh potential benefits against any theoretical risks. Limited data exist for breastfeeding, and a decision should be made with medical guidance.

To order Infeflox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Infeflox (ceftriaxone) offers a long half‑life allowing once‑daily dosing, broad Gram‑negative coverage, and stability against many β‑lactamases, distinguishing it from earlier‑generation cephalosporins that may require multiple daily doses. Compared with penicillins, it provides enhanced activity against resistant strains such as Haemophilus influenzae and certain Enterobacteriaceae.

Infeflox should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light, and must not be frozen or shaken vigorously. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions until administration.

Infeflox is supplied as a sterile powder for injection and is reconstituted with a compatible diluent. It can be given either intravenously or intramuscularly, depending on the clinical situation and prescriber preference. Administration should be performed by qualified healthcare personnel using aseptic technique.

Serious adverse events include anaphylaxis or severe hypersensitivity reactions, Clostridioides difficile‑associated colitis, and severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Clinicians should monitor patients for signs of these conditions and discontinue therapy promptly if they occur.

Infeflox is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation. It should also be avoided in neonates (≤28 days) receiving calcium‑containing solutions due to the risk of precipitation. Caution is advised in patients with severe hepatic or renal impairment, and prescribers should assess each case individually.